Impact of frailty on hospitalized patients with prostate cancer: A retrospective analysis.

e23054 Background: The impact of Hospital frailty risk score on outcomes in hospitalized patients with prostate cancer has not been previously studied. This research aimed to examine the association between frailty and prostate cancer outcomes. Methods: This retrospective study utilized hospitalization data from the National Inpatient Sample (NIS) between January 1, 2020, and December 31, 2020. Data of patients with a primary or secondary discharge diagnosis of prostate cancer (ICD10-CM codes C61. 0, D07. 5, and Z85. 46) were obtained. The objective was to evaluate the correlation between frailty and prostate cancer. Multivariate analysis was performed, stratified by race, age, Charlson index, median annual income in the patient's zip code, hospital bed size, teaching status, and census division of the hospital. Results: A total of 51, 980 hospitalizations for prostate cancer were identified, with 72. 7% in the intermediate to high frailty score (IHFS) group and 27. 3% in the low frailty score (LFS) group. The IHFS group had a higher unadjusted in-hospital mortality rate than the LFS group (5. 85% vs. 1. 2%). Patients with IHFS had increased odds of adjusted mortality compared to those with LFS (adjusted odds ratio aOR = 4. 45, 95% Cl 3. 80-5. 22, P < 0. 01). Hispanic and Black race patients also had increased odds of adjusted mortality compared to Caucasian race patients (aOR = 1. 42, 95%CI 1. 19-1. 70, P < 0. 01) ; aOR = 1. 16, 95%CI 1. 00-1. 32, P = 0. 037, respectively). Additionally, the IHFS group had longer lengths of stay (5. 65 ± 0. 038 vs. 3. 26 ± 0. 28 days) and higher adjusted total costs (66, 107 ± 850 vs. 64, 308 ± 1066) compared to the LFS group. Conclusions: Patients with prostate cancer and a high hospital frailty risk score exhibited significantly higher mortality rates, longer lengths of stay, and increased total adjusted costs. Frailty assessment plays a crucial role in predicting outcomes in patients with prostate cancer. Physicians can use frailty assessment to stratify patients based on risk and improve their ability to anticipate consequences.